Myeloma – new approaches to combined nephrological–haematological management
Authors:
- Marion HaubitzMHMarion Haubitz
- Dietrich PeestDPDietrich Peest
Open Access
- 5 January 2006
- journal article
- research article
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 21 (3) , 582-590
Abstract
Multiple myeloma (MM) is a haematopoietic malignancy of terminal differentiated clonal plasma cells. The clinical symptoms are caused by diffuse or multilocular infiltration of the bone marrow with osteolysis and suppression of the normal haematopoesis, as well as by the production of monoclonal immunoglobulins or fragments (light chains or heavy chains). The incidence is approximately 3–4/100 000/year. MM is a disease of the elderly. Approximately 15% of patients are aged 60 years or younger and a further 15% between 60 and 65 years. Fewer than 2% of the patients are younger than 40 years at diagnosis. This age distribution has implications for the population eligible for specific types of treatment, such as high-dose therapy and stem cell transplantation.Keywords
This publication has 62 references indexed in Scilit:
- Melphalan 200 mg/m2 with blood stem cell support as first-line myeloma therapy: impact of glomerular filtration rate on engraftment, transplantation-related toxicity and survivalBone Marrow Transplantation, 2005
- Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myelomaBlood, 2003
- Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myelomaBlood, 2002
- Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myelomaBlood, 2002
- An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosisBone Marrow Transplantation, 2001
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999
- High-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal insufficiencyBone Marrow Transplantation, 1997
- Acute myeloma kidneyKidney International, 1995
- Induction and maintenance therapy in multiple myeloma: a multicenter trial of MP versus VCMPEuropean Journal of Cancer and Clinical Oncology, 1988
- Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimensJAMA, 1969